- Home
- PGP vs IMAB Comparison
PGP vs IMAB Comparison
Compare PGP & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGP
- IMAB
- Stock Information
- Founded
- PGP 2003
- IMAB 2014
- Country
- PGP United States
- IMAB United States
- Employees
- PGP N/A
- IMAB N/A
- Industry
- PGP Finance Companies
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PGP Finance
- IMAB Health Care
- Exchange
- PGP Nasdaq
- IMAB Nasdaq
- Market Cap
- PGP 95.8M
- IMAB 83.8M
- IPO Year
- PGP N/A
- IMAB 2020
- Fundamental
- Price
- PGP $7.84
- IMAB $0.94
- Analyst Decision
- PGP
- IMAB Strong Buy
- Analyst Count
- PGP 0
- IMAB 3
- Target Price
- PGP N/A
- IMAB $8.00
- AVG Volume (30 Days)
- PGP 39.8K
- IMAB 288.7K
- Earning Date
- PGP 01-01-0001
- IMAB 08-28-2024
- Dividend Yield
- PGP 10.84%
- IMAB N/A
- EPS Growth
- PGP N/A
- IMAB N/A
- EPS
- PGP N/A
- IMAB N/A
- Revenue
- PGP N/A
- IMAB $3,313,984.00
- Revenue This Year
- PGP N/A
- IMAB N/A
- Revenue Next Year
- PGP N/A
- IMAB N/A
- P/E Ratio
- PGP N/A
- IMAB N/A
- Revenue Growth
- PGP N/A
- IMAB N/A
- 52 Week Low
- PGP $5.83
- IMAB $0.90
- 52 Week High
- PGP $7.81
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- PGP 34.97
- IMAB 38.29
- Support Level
- PGP $7.82
- IMAB $0.91
- Resistance Level
- PGP $8.20
- IMAB $1.11
- Average True Range (ATR)
- PGP 0.13
- IMAB 0.07
- MACD
- PGP -0.04
- IMAB -0.00
- Stochastic Oscillator
- PGP 3.39
- IMAB 13.01
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).